• Portfolio company DualityBio signed a global collaboration, licensing deal with Roche unit Genentech to develop next-generation ADCs.
• DualityBio will receive an upfront payment of USD 45 million.
• Deal includes potential development, regulatory, commercialization milestones exceeding USD 1 billion, with tiered royalties on annual net sales.
• DualityBio will lead discovery, early global clinical work; Genentech takes exclusive global rights, later-stage development, commercialization post-Phase 1a.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Fujian Yangming Venture Capital Co Ltd published the original content used to generate this news brief on August 28, 2026, and is solely responsible for the information contained therein.